Chimerix Announces Acquisition by Jazz Pharmaceuticals for $935 Million

New York – March 5, 2025 – Cooley advised Chimerix (Nasdaq: CMRX), a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, on its definitive agreement to be acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) for $8.55 per share in cash – totaling approximately $935 million. The transaction has been approved by both companies and is expected to close in the second quarter of 2025.

Partners Jason Kent and Kevin Cooper led the Cooley team advising Chimerix.

Cooley has served as Chimerix’s primary outside counsel for 23 years, advising the company throughout its life cycle on multiple private financings, its 2013 initial public offering, and numerous major fundraising and M&A transactions as a public company – such as its 2021 acquisition of neuro-oncology company Oncoceutics, which provided Chimerix with its lead clinical asset, dordaviprone.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.